PharmaZell, a German-based producer of speciality APIs, and France’s CDMO Groupe Novasep are to merge under the ownership of PharmaZell’s current majority shareholder, private equity firm Bridgepoint. This remains subject to consultation with employees and other closing conditions.
Curia has announced plans to invest about $35 million in order to expand commercial-scale API manufacturing capacity at its largest site in Rensselaer, New York, over the course of 18 months. This is the third significant announcement in the month since the former AMRI renamed itself.
Heraeus Pharmaceutical Ingredients (HPI) has announced that its new production line for platinum-based pharmaceutical ingredients at its headquarters in Hanau, Germany, is now running at full speed and customers have already received the first deliveries of APIs. The company launched the project in late 2018 in response to growing demand for oncology drugs and imminent shortages. HPI, a business line of Heraeus Precious Metals, is world’s largest supplier of platinum-based HPAPIs, which are used in numerous therapies, notably lung, colorectal, ovarian and testicular cancer.
Novasep has announced a €6.1 million investment to modernise API manufacturing at its site in Mourenx, south-west France. This followed on shortly after a €4 million investment had been announced at its main HPAPIs site at Le Mans.
Via the former investment, Novasep will install new equipment and revamp clean rooms for API isolation at Mourenx, creating seven new jobs. The company said that this will “enhance Novasep’s flexibility and develop a high-performance capacity for the custom manufacturing of innovative therapeutic molecules”.
The Biden administration has announced plans to tackle the US’s dependency on imports for critical medicines, with a new strategy that will seek to drive the ‘reshoring’ of some manufacturing. This follows a multi-industry review of key supply chains, occasioned by an executive order in February.
In a pre-close trading update for the financial year ended 31 March 2021, Johnson Matthey (JM) CEO Robert MacLeod revealed that: “We have commenced a strategic review of Health, as we continue to focus resources to maximise value for our shareholders”.
Full results will be announced on 27 May but it is known that Health, which offers API custom manufacturing services, controlled substances, catalysts and generics, generated sales of £223 million, about 5% of the total sale. The division’s full-year operating performance is expected to be above the prior year.
New Jersey-based PMC Group International, a diversified manufacture of chemicals and pharmaceuticals, has acquired Cobra Investments Management from a consortium of previous owners. This includes Copperhead Chemical, which has a 350-hectare site at Tamaqua, Pennsylvania. Terms were not disclosed.